ROCHESTER, Mich., May 02, 2018 -- OptimizeRx Corp. (OTCQB:OPRX), the nation’s leading provider of digital health messaging for the pharmaceutical industry, has entered into a definitive agreement with two institutional investors and a large family office for a private offering of common stock.
OptimizeRx will issue 5 million shares of its common stock to the investors at $1.80 per share, resulting in aggregate gross proceeds of $9 million to the company. The company intends to use the proceeds for general corporate purposes.
“Our record Q1 results demonstrate the strong momentum in our business, including growth in pharma brands, channel partners, and healthcare providers on the OptimizeRx network,” said OptimizeRx CEO, William Febbo. “We expect to use some of the proceeds from this capital raise to fund additional sales and channel investments in our core ambulatory market, where we continue to demonstrate high ROI for our pharma clients’ marketing spend. It will also support our further expansion into the hospital channel, which represents a significant growth opportunity.”
Lake Street Capital Markets is acting as the sole placement agent, with B. Riley FBR acting as an advisor to the transaction.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About OptimizeRx
OptimizeRx® (OTCQB:OPRX) is the nation’s leading provider of digital health messaging via electronic health records (EHRs), providing a direct channel for pharma companies to communicate with healthcare providers. The company’s cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, education, and critical clinical information. The company’s network is comprised of leading EHR platforms like Allscripts, Amazing Charts and Quest, and provides more than half of the ambulatory market access to these benefits within their workflow at the point of care. For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
OptimizeRx Contact:
Doug Baker, CFO
Tel (248) 651-6568 x807
[email protected]
Investor Relations Contact:
Ron Both, CMA
Tel (949) 432-7557
[email protected]


Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints
Japan Earthquake Disrupts Auto and Chip Supply Chains
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat
Same sparkle, different story: how lab-grown diamonds are transforming the market
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight
World game at war: why some European nations have threatened a World Cup boycott 



